iBET scientists attend meeting of European consortium CARxALL in Madrid

A delegation of scientists from iBET’s Stem Cell Bioengineering and Translational Immunology labs recently participated in the first meeting of 2024 of the CARxALL project, hosted at the Severo Ochoa Center for Molecular Biology (CBMSO) in Madrid, Spain.
CARxALL is a European consortium, led by OneChain Immunotherapeutics and funded by the European Innovation Council (EIC), focused on developing a promising CAR-T therapy against paediatric leukaemia and bring it to the clinical practice.
Along with scientists from OneChain Immunotherapeutics and iBET, representatives from the remaining project partners - Josep Carreras Leukaemia Research Institute and CBMSO - were also present.
The primary goal of this meeting was to address the main challenges encountered in the project thus far and align the objectives and action plan for the upcoming year.

CARxALL was initiated in 2023 and is expected to last three years. iBET’s contribution focuses on the translation of the production process to an industrial level, coordinated by Margarida Serra (Head of the Stem Cell Bioengineering Lab).